June 18, 2020 -- Lyell Immunopharma and Pact Pharma have formed a strategic partnership to jointly develop and test a next-generation personalized anticancer T-cell therapy against solid tumors.
The companies will develop personalized T-cell therapy using the patient's own T cells through nonviral precision genome engineering for tumor neoantigen specificity. This therapy aims to overcome potential tumor resistance and T-cell exhaustion.
Pact will receive upfront and milestone payments from the partnership. If successful, the drug development program will be jointly owned and each company will share profits equally.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
